Latest news with #NeuroPace
Yahoo
4 days ago
- Business
- Yahoo
NeuroPace Secures Up to $75 Million in Debt Financing
MOUNTAIN VIEW, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company has entered into a new $75 million credit facility with MidCap Financial, consisting of a $60 million term loan and a $15 million revolving credit facility. Proceeds from the new term loan were used to fully repay NeuroPace's term loan with CRG Partners IV, L.P., with proceeds of the new revolving credit facility available for working capital needs and other corporate purposes. 'We are pleased to partner with MidCap Financial on this new credit facility, which provides non-dilutive capital at favorable terms that reduce our cash interest expense and support the continued growth of our business,' said Joel Becker, Chief Executive Officer of NeuroPace. 'The proceeds and improved structure provide us the financial strength and flexibility to continue expanding patient access to the RNS® System and to invest in key growth initiatives, including site-of-service expansion, new indications, direct-to-consumer programs, new product development and real-world evidence generation. We also want to thank CRG for their partnership and support over the past several years. They have been an excellent partner in the Company's development.' The Company's new loan agreement includes a maturity date of five years for both the term loan and revolving credit facility. The annual interest rate is equal to SOFR subject to a floor of 2%, plus (1) 5.5% under the term loan and (2) 3.75% under the revolving loan. Armentum Partners served as financial advisor to NeuroPace on the transaction. Additional detail regarding the foregoing financing is set forth in NeuroPace's Current Report on Form 8-K, filed today with the U.S. Securities and Exchange Commission. About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. About MidCap Financial MidCap Financial is a middle-market focused, specialty finance firm that provides senior debt solutions to companies across all industries. As of March 31, 2025, MidCap Financial provides administrative or other services for approximately $55 billion of commitments*. MidCap Financial is managed by Apollo Capital Management, L.P., a subsidiary of Apollo Global Management, Inc., pursuant to an investment management agreement. Apollo had assets under management of approximately $785 billion as of March 31, 2025, in credit, private equity and real assets funds. For more information about MidCap Financial, please visit For more information about Apollo, please visit *Including commitments managed by MidCap Financial Services Capital Management LLC, a registered investment adviser, as reported under Item 5.F on Part 1 of its Form ADV Forward Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. NeuroPace may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding: NeuroPace's expectations, forecasts and beliefs regarding the use of proceeds from the term loan and revolving credit facility with MidCap Financial. NeuroPace may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including those described more fully in the section titled 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and elsewhere in NeuroPace's public filings with the U.S. Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 13, 2025, as well as any other reports that it may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to NeuroPace as of the date hereof. NeuroPace undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace's views as of any date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of NeuroPace. Investor Contact:Scott SchaperHead of Investor Relationssschaper@
Yahoo
29-05-2025
- Business
- Yahoo
H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating
On May 28, H.C. Wainwright analyst Yi Chen initiated coverage of NeuroPace, Inc. (NASDAQ:NPCE) with a Buy rating and a price target of $18. The rating comes after the company released preliminary results for one-year data in NAUTILUS study. On May 27, the company announced key results from its NAUTILUS study, the first clinical trial evaluating its RNS system for drug-resistant idiopathic generalized epilepsy. The study met its primary safety endpoint at 12 weeks post-implant, demonstrating a low rate of serious adverse events and reinforcing the device's established safety profile. The analyst noted that the system demonstrated significant seizure reduction in the clinical stage. A close-up of a medical device being calibrated and tested in a clinical laboratory setting. Moreover, NeuroPace, Inc. (NASDAQ:NPCE) delivered robust results for the fiscal first quarter of 2025. The revenue grew more than 24% year-over-year to $22.52 million and surpassed expectations by $676,490, whereas the EPS of $-0.21 also exceeded consensus by $0.03. The analyst said that the stock has appreciated over 150% during the past year and the recent data from the study presents an attractive entry point for investors. NeuroPace Inc. (NASDAQ:NPCE) is a commercial-stage medical device company that develops the RNS system. RNS system is an implantable brain-responsive device designed to reduce or prevent seizures in people with drug-resistant epilepsy. While we acknowledge the potential of NPCE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NPCE and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?
NeuroPace, Inc. (NASDAQ:NPCE) released preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for drug-resistant idiopathic generalized epilepsy (IGE). The study met its primary 12-week post-implant safety endpoint, demonstrating a low rate of serious adverse events related to the device and implant procedure. The study did not reach statistical significance for the primary effectiveness endpoint in the overall study population, which was to show a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation the data did show a clinically meaningful and statistically significant response in the primary effectiveness endpoint within a subgroup of patients with lower baseline frequency of generalized tonic-clonic seizures, representing most trial participants. Additionally, the company said that within the entire trial population, clinically relevant data, including median percent seizure reduction, responder rates, and improvement in seizure-free days, showed numerically robust and clinically meaningful improvements over the first year of treatment and continued in those who have progressed to the second year. The company will engage with the FDA to discuss regulatory pathways based on the data. These discussions may include the possibility of utilizing the overall median seizure reduction data across the full study population and pursuing a more targeted indication focused on patients with lower baseline seizure frequency who may represent a majority of IGE patients. In April, NeuroPaces terminated its distribution relationship for SEEG products and will begin winding down the relationship in the fourth quarter of 2025 and continuing through the first quarter of 2026. NeuroPace announced three-year effectiveness data from the Post-Approval Study (PAS) of the RNS System in April. The data showed an 82% median reduction in seizures in adults treated with brain-responsive stimulation for drug-resistant focal epilepsy and seizure freedom, with 42% of patients remaining seizure-free for 6+ months. Sales grew 24% to $22.5 million in the first quarter of 2025. RNS System revenue grew 29%, excluding revenue from implants in the NAUTILUS study in the first quarter of 2024. Increased sales of the RNS System primarily drove the company's revenue growth. The company also continued to generate meaningful revenue from sales of SEEG products. NeuroPace raised the fiscal year 2025 sales guidance from $92 million-$96 million to $93 million-$97 million compared to the consensus of $93.64 million. Price Action: NPCE stock is down 33.90% at $11.68 at the last check Tuesday. Read Next:Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data? originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
15-05-2025
- Business
- Yahoo
NeuroPace, Inc.'s (NASDAQ:NPCE) large institutional owners must be happy as stock continues to impress, up 29% over the past week
Given the large stake in the stock by institutions, NeuroPace's stock price might be vulnerable to their trading decisions The top 6 shareholders own 51% of the company Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. To get a sense of who is truly in control of NeuroPace, Inc. (NASDAQ:NPCE), it is important to understand the ownership structure of the business. We can see that institutions own the lion's share in the company with 41% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company. And things are looking up for institutional investors after the company gained US$115m in market cap last week. The gains from last week would have further boosted the one-year return to shareholders which currently stand at 73%. Let's take a closer look to see what the different types of shareholders can tell us about NeuroPace. See our latest analysis for NeuroPace Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. We can see that NeuroPace does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of NeuroPace, (below). Of course, keep in mind that there are other factors to consider, too. It looks like hedge funds own 7.4% of NeuroPace shares. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. Accelmed Partners is currently the company's largest shareholder with 14% of shares outstanding. In comparison, the second and third largest shareholders hold about 10% and 7.6% of the stock. We also observed that the top 6 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. We can see that insiders own shares in NeuroPace, Inc.. As individuals, the insiders collectively own US$15m worth of the US$425m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling. The general public, who are usually individual investors, hold a 24% stake in NeuroPace. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. With an ownership of 24%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public. While it is well worth considering the different groups that own a company, there are other factors that are even more important. For instance, we've identified 1 warning sign for NeuroPace that you should be aware of. Ultimately the future is most important. You can access this free report on analyst forecasts for the company. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 19.23%. A quarter ago, it was expected that this company would post a loss of $0.25 per share when it actually produced a loss of $0.18, delivering a surprise of 28%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. NeuroPace , which belongs to the Zacks Medical - Instruments industry, posted revenues of $22.52 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.87%. This compares to year-ago revenues of $18.12 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. NeuroPace shares have added about 19.5% since the beginning of the year versus the S&P 500's decline of -0.6%. While NeuroPace has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for NeuroPace: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.25 on $23.26 million in revenues for the coming quarter and -$0.79 on $94.38 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Sensus Healthcare, Inc. (SRTS), another stock in the same industry, has yet to report results for the quarter ended March 2025. The results are expected to be released on May 15. This company is expected to post quarterly earnings of $0.04 per share in its upcoming report, which represents a year-over-year change of -71.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Sensus Healthcare, Inc.'s revenues are expected to be $7.27 million, down 31.8% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NeuroPace, Inc. (NPCE) : Free Stock Analysis Report Sensus Healthcare, Inc. (SRTS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
